

Research

Open Access

Allelic dimorphism of the erythrocyte binding antigen-175 (*eba-175*) gene of *Plasmodium falciparum* and severe malaria: Significant association of the C-segment with fatal outcome in Ghanaian children

Jakob P Cramer¹, Frank P Mockenhaupt¹, Ingo Möhl¹, Sabine Dittrich¹, Ekkehardt Dietz², Rowland N Otchwemah³, Stephan Ehrhardt⁴, Ulrich Bienzle¹ and Tomas Jelinek*¹

Address: ¹Berlin Institute of Tropical Medicine, Berlin, Germany, ²Institute for International Health Sciences, Humboldt University, Berlin, Germany, ³School of Medicine and Health Sciences, University of Development Studies, Tamale, Ghana and ⁴Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany

Email: Jakob P Cramer - jakob.cramer@charite.de; Frank P Mockenhaupt - frank.mockenhaupt@charite.de; Ingo Möhl - moehl@bbges.de; Sabine Dittrich - sabine-dittrich@gmx.de; Ekkehardt Dietz - lungtung@zedat.fu-berlin.de; Rowland N Otchwemah - UIDS@ug.apc.org; Stephan Ehrhardt - ehrhardt@bni-hamburg.de; Ulrich Bienzle - ulrich.bienzle@charite.de; Tomas Jelinek* - jelinek@bbges.de

* Corresponding author

Published: 12 May 2004

Received: 09 January 2004

Malaria Journal 2004, **3**:11

Accepted: 12 May 2004

This article is available from: <http://www.malariajournal.com/content/3/1/11>

© 2004 Cramer et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: The erythrocyte binding antigen-175 (EBA-175) on *Plasmodium falciparum* merozoites mediates sialic acid dependent binding to glycoprotein A on host erythrocytes and, therefore, plays a crucial role in cell invasion. Dimorphic allele segments have been found in its encoding gene with a 342 bp segment present in FCR-3 strains (F-segment) and a 423 bp segment in CAMP strains (C-segment). Possible associations of the dimorphism with severe malaria have been analysed in a case-control study in northern Ghana.

Methods: Blood samples of 289 children with severe malaria and 289 matched parasitaemic but asymptomatic controls were screened for *eba-175* F- and C-segments by nested polymerase chain reaction.

Results: In children with severe malaria, prevalences of F-, C- and mixed F-/C-segments were 70%, 19%, and 11%, respectively. The C-segment was found more frequently in severe malaria cases whereas mixed infections were more common in controls. Infection with strains harbouring the C-segment significantly increased the risk of fatal outcome.

Conclusion: The results show that the C-segment is associated with fatal outcome in children with severe malaria in northern Ghana, suggesting that it may contribute to the virulence of the parasite.

Introduction

Malaria parasites invade host erythrocytes via interaction between merozoite surface ligands and erythrocyte recep-

tors [1,2]. In *Plasmodium falciparum*, the erythrocyte binding antigen-175 (EBA-175) is one of the most important ligands mediating erythrocyte invasion by sialic acid

dependent binding to glycophorin A [3,4]. The 175 kDa protein is located in micronemes at the apical end of the merozoite [5]. Together with the Duffy-binding protein of *Plasmodium vivax* (PvDBP), EBA-175 belongs to a family of parasite adhesion molecules, the Duffy-binding-like erythrocyte-binding proteins (DBL-EBP) [6]. This protein family is characterized by a N-terminal signal peptide, cystein-rich Duffy-binding-like (DBL) domains, a carboxyl cysteine-rich region (c-cys), a transmembrane domain and a short cytoplasmic tail. Encoding genes are members of the erythrocyte-binding-like (*eb1*) gene family. The *eba-175* gene is located on chromosome 7 and consists of four exons [7,8]. A large exon 1 is divided into regions I-VI and codes for a tandem array of two DBL domains in region II (F1 and F2) forming the putative ligand site as well as the c-cys domain, region VI. Both domains have numerous conserved cysteine and hydrophobic amino acid residues supporting their functional relevance. They are separated by highly divergent dimorphic segments in region III [9]. This dimorphism is characterized by an insertion of either a 342 bp segment in FCR-3 strains (F-segment) or a 423 bp segment in CAMP strains (C-segment) [7,10]. Both segments share little homology and are located at slightly different positions with the F-segment being 273 bp upstream of the C-segment. These two variants are conserved in all strains isolated so far and since *Plasmodium* merozoites are haploid either one or the other, but never both or neither segment is present in one individual parasite clone [10]. The functional relevance of the F-/C-segment dimorphism remains unknown. Human IgG antibodies recognize epitopes on the dimorphic F- and C-segments but are not associated with protection from clinical malaria in The Gambia [11]. Population genetic analysis showed a C-segment allele frequency of 73% in *eba-175* of *P. falciparum* in a Sudanese population whereas more than 70% of isolates from The Gambia, Nigeria, Cameroon, Gabon, Tanzania and South Africa carried the F-segment [12,13].

The two variants of the *eba-175* dimorphism are evolutionarily conserved suggesting functional relevance. F- and C-segment frequencies vary in different ethnicities and geographic regions. It is, therefore, hypothesized that this dimorphism may influence clinical disease and outcome.

Methods

Study area and parasites

Samples were collected between August and November 2002 in Tamale and its vicinity, Northern Region, Ghana. Climate and vegetation are savannah-type. Malaria transmission is perennial but highly seasonal and infection rates are consistent with a hyperendemic malaria situation (Mockenhaupt et al., unpublished data). Blood samples and clinical data were obtained from 290 children

(aged 6 months to 9 years) with severe falciparum malaria (SM) according to the current WHO definition [14]. One sample was lost for genetic analysis. The clinical and parasitological characteristics of these children are described in detail elsewhere [15]. For each patient with SM, one age- and sex-matched asymptomatic but parasitaemic control was randomly selected from a survey representative for Tamale and the surrounding six districts. For that purpose, 30 communities and census units were recruited following a two-stage cluster sampling strategy with probability proportional to population size. Within each unit, ≥ 70 children aged 6 months to 9 years were randomly selected, clinical examinations were performed and venous blood samples were taken. Parasites were counted per ≥ 200 white blood cells on Giemsa-stained thick blood films and *P. falciparum* was substantiated by specific PCR assays [16].

DNA extraction and genotyping

Blood was stabilized (AS1, Qiagen, Hilden, Germany), stored at 4°C and DNA was extracted by commercial kits (QIAmp blood kit, Qiagen, Hilden, Germany). Genotyping of the *eba* dimorphism was performed by nested PCR using primers EBA1 5'-CAAGAAGCAGTTCCTGAGGAA-3' (forward) and EBA2 5'-TCTCAACATTCATATTAACAATTC-3' (reverse) for the first amplification and EBA3 5'-GAGGAAAACACTGAAATAGCACAC-3' (forward) and EBA4 5'-CAATTCCTCC-AGACTGTTGAACAT-3' (reverse) for the second amplification [17]. The following mixture was used for 20 μ l reaction volume [18]: 4 μ l (50–200 ng) of DNA-template for the first amplification and 2 μ l PCR-product for the nested PCR; 1 μ l of each primer (100 μ M), 1 U HotStarTaq Polymerase (Qiagen®, USA); 1x PCR-Buffer, 1,5 mM magnesium chloride; and 200 μ M dNTP. PCR was performed on T3 Thermocycler (Biometra®, Germany) using the following conditions: Initial 5-min denaturation at 94°C followed by 29 cycles with 1-min at 94°C, 1-min at 56°C and 2-min 72°C and a 3-min final extension at 72°C. Amplicons were separated on 1.5% ethidiumbromide stained agarose gels and visualized using UV-transillumination. A single band of 795 or 714 bp identified infection with parasites containing the F- or C-segment, respectively. Samples showing both bands reflected mixed infection with a minimum of two different clones.

Statistical analysis

Geometric mean parasite density (GMPD) and 95% confidence intervals (95% CI) were calculated after \log_{10} transformation. Genotype frequencies were compared between case and control groups using Pearson Chi-Square test and Fisher's exact test as applicable. Subgroup analysis of the risk of individual symptoms was performed by conditional logistic regression models. Associations between genotypes and fatal outcome in severe

Table 1: Matched pair analysis of children with severe malaria and asymptomatic parasitaemic controls: risk of symptoms and conditions of severe malaria

Condition/Symptom	Dimorphism	Severe malaria absolute number (%)	Parasitaemic controls	OR [95% CI] P value (F-segment as reference)
All (n = 289)	F-segment	201 (70)	176 (61)	
	F-/C-segment	33 (11)	64 (22)	.5 [.3-.7] .003
	C-segment	55 (19)	49 (17)	1.0 [.6-1.7] 1
Severe anaemia (n = 159)	F-segment	114 (72)	95 (60)	
	F-/C-segment	18 (11)	37 (23)	.4 [.2-.8] .02
	C-segment	27 (17)	26 (16)	.9 [.4-1.8] .9
Prostration (n = 97)	F-segment	67 (69)	55 (57)	
	F-/C-segment	10 (10)	23 (24)	.4 [.1-1.0] .06
	C-segment	20 (21)	18 (19)	.8 [.3-2.0] .8
Respiratory Distress (n = 66)	F-segment	40 (61)	47 (71)	
	F-/C-segment	9 (14)	10 (15)	1.2 [.4-3.7] 1
	C-segment	17 (26)	9 (14)	2.0 [.8-7.7] .2
Multiple Convulsions (n = 59)	F-segment	40 (68)	36 (61)	
	F-/C-segment	6 (10)	15 (25)	.4 [.1-1.1] .1
	C-segment	13 (22)	8 (14)	2.0 [.6-6.3] .4
Impaired Consciousness (n = 56)	F-segment	36 (64)	39 (70)	
	F-/C-segment	8 (14)	9 (16)	1 [.3-3.6] 1
	C-segment	12 (21)	8 (14)	1.6 [.5-4.6] .6
Jaundice (n = 34)	F-segment	23 (68)	21 (62)	
	F-/C-segment	3 (9)	6 (18)	.5 [.04-2.5] .7
	C-segment	8 (24)	7 (21)	1 [.3-3.6] 1
Circulatory collapse (n = 10)	F-segment	6 (60)	8 (80)	
	F-/C-segment	0 (0)	1 (10)	-
	C-segment	4 (40)	1 (10)	3.0 [.4-3.0] .6
Haemoglobinuria (n = 8)	F-segment	6 (75)	5 (63)	
	F-/C-segment	0 (0)	1 (13)	-
	C-segment	2 (25)	2 (25)	.5 [0-4.9] 1
Hyperparasitaemia (n = 64)	F-segment	43 (67)	47 (73)	
	F-/C-segment	6 (9)	10 (16)	.4 [.1-1.6] .3
	C-segment	15 (23)	7 (11)	3.7 [1.1-13.1] .06
Fatal outcome (n = 32)	F-segment	15 (47)	18 (56)	
	F-/C-segment	4 (13)	7 (22)	.5 [.04-2.5] .7
	C-segment	13 (41)	6 (19)	4.0 [.9-19.4] .1


malaria cases were corrected for known predictors of mortality (impaired consciousness, circulatory collapse, hypoglycaemia and malnutrition [15]) by multiple logistic regression analysis. A *P*-value < .05 was considered as statistically significant.

Results

The median age of the 289 children with severe malaria (154 girls, 135 boys) was 24 months (range 6-102). Mean rectal temperature (\pm SD) was 38.6°C (\pm 1.1). GMPD was 30,200/ μ L (95% CI, 22,474-40,581) and hyperparasitaemia (>250,000/ μ L) was present in 64 children (22%). The GMPD of parasitaemic controls was 1,738/ μ L (95% CI, 1,387-2,178). Cases exhibited the following symptoms defining severe malaria (WHO 2000): severe anemia (55%), prostration (34%), respiratory distress (23%),

multiple convulsions (20%), impaired consciousness (19%), jaundice (12%), circulatory collapse (3%), and haemoglobinuria (3%). Case fatality rate was 11% (32/284). For five children, no data on outcome were available since they absconded during hospitalization.

In children with severe malaria, the F- and C-segment were present in 70% (201/289) and 19% (55/289), respectively (see Table 1). Both segments were found in 11% (33/289) representing mixed infections. In the parasitaemic controls, the prevalences for the F- and C-segment were 61% (176/289) and 17% (49/289), respectively. Mixed infections were significantly less frequent in severe cases than in parasitaemic controls (11% (33/289) versus 22% (64/289); OR .5, [95% CI .3-.7], *P* = .003; F-segment used as reference). Matched pair analy-



* $\chi^2_{trend} = 11.3; P\text{-value} = .0008$

Figure 1
 eba-175 dimorphism (F-segment, F-/C-mixed infection, C-segment): Percentage (absolute numbers) of severe malaria cases with respective symptoms, conditions, and outcome.

sis revealed no significant associations of the C- or F-segment with individual symptoms and conditions of SM (Table 1). However, for all symptoms and conditions of SM except for haemoglobinuria, the C-segment was more common in severe cases while mixed infections occurred

more often in respective parasitaemic controls (not significant).

A trend towards a higher risk of dying of severe malaria was found in children with the C-segment in matched pair

analysis (OR 4.0, [95% CI .9–19.4], $P = .1$; Table 1). Associations of the *eba-175* dimorphism with symptoms, conditions, and outcome within the group of severe malaria cases were re-tested (Figure 1). The C-segment was significantly associated with fatal outcome (case fatality rates: F-segment: 8%, F/C-segment: 13%, C-segment: 24%; $\chi^2_{\text{trend}} = 11.3$, $P = .0008$). Logistic regression analysis adjusting for known predictors of death in these children [15] confirmed a six-fold increased risk of fatal outcome in patients infected with C-segment parasites as compared to F-segment parasites (OR 5.6, [95% CI 1.8–17.1], $P < .003$; other predictors were: impaired consciousness, OR, 9.3; 95% CI, 3.4–25.9; $P < .0001$; circulatory collapse, OR, 35.9; 95% CI, 4.5–290; $P = .0008$; hypoglycemia, OR, 3.7; 95% CI, 1.3–10.3; $P = .01$; malnutrition, OR, 95% CI, 2.5; 1.0–6.3; $P = .06$).

Discussion

This study aimed at evaluating the frequencies of a dimorphic allele segment in the gene encoding the erythrocyte binding antigen-175 on *P. falciparum* merozoites in children with severe malaria in northern Ghana. Second, associations of the *eba-175* dimorphism with symptoms, conditions, and outcome of severe disease were assessed in a case-control analysis.

In 289 Ghanaian children with severe malaria, the F-segment predominated (70%). C-segment and mixed infections were present in 19% and 11%, respectively. These findings are consistent with recently published data from West Africa [13].

In the case-control analysis, mixed infections were significantly more common in controls than in cases. This is in accordance with findings from other areas with high transmission [19,20] and is considered to indicate acquired immunity [21]. However, the presence of either the F- or the C-segment alone does not exclude the possibility of infection with different strains and, therefore, limits validity of this finding. The overall distribution of the F- and C-alleles did not differ significantly between groups arguing against a role for the *eba* dimorphism in mediating severe malaria *per se*. This is consistent with the finding in the Gambia that antibodies against the dimorphism do not protect against clinical malaria [11]. Yet, within the group of children with severe malaria, fatal outcome was significantly associated with the C-segment (Figure 1). These findings suggest that the C-segment of the *eba-175* dimorphism on *P. falciparum* merozoites is associated with fatality in severe malaria rather than promoting disease progression from asymptomatic parasitaemia towards severe disease. A longitudinal study is needed to confirm this.

Unlike in West Africa, in a Sudanese population the C-segment was most frequent [13]. This part of Africa represents an ethnically distinct region with lower malaria endemicity. In a study conducted in Laos, the dimorphism was unequally distributed in distinct ethnic minorities [18]. Random shifts in parasite allele frequencies in different geographic regions can serve as an explanation. Also, susceptibility to infection and disease severity vary in different regions as does genetic variability in host populations. On the other hand, not only genetic differences in the host but also in the parasite may influence disease severity and outcome. Although the functional mechanism of the *eba-175* dimorphism regarding disease severity remains unclear one might postulate that this dimorphism offers alternative ways of erythrocyte invasion to the parasite and therefore allows more rapid replication. Since the *eba-175* dimorphism appears not to be involved in the binding to neuraminidase- or trypsin-sensitive erythrocyte receptors [22] it may recognize other, as yet unknown, receptors. This explanation is supported by the finding that the C-segment was associated at borderline statistical significance with hyperparasitaemia (OR 3.7 [1.1–13.1] $P = .06$, see Table 1).

In conclusion, the C-segment of the *eba-175* allelic dimorphism on *P. falciparum* merozoites is not associated with severe malaria *per se* but confers a higher risk of fatal disease in northern Ghana. These findings may contribute to the development of a diagnostic tool predicting disease outcome in children. Further studies are necessary to reveal its functional relevance.

Authors' contributions

TJ and FP Mockenhaupt had the original idea for the study. IM and SD did the polymorphism analysis. FPM, SE, UB and RNO were involved in the recruitment of cases and controls. ED and JPC did statistical analysis. JPC, FPM and TJ wrote the report with major contributions of the other authors.

Acknowledgements

We thank all participating children and their parents. We also thank all members of the Northern Region Malaria Projects (NORMAP) and the Medical Faculty Charité, Humboldt University Berlin, for financial support.

Financial support: Charité grant 2003-676

References

1. Bannister LH, Dluzewski AR: **The ultrastructure of red cell invasion in malaria infections: a review.** *Blood Cells* 1990, **16**:257-292.
2. Chitnis CE: **Molecular insights into receptors used by malaria parasites for erythrocyte invasion.** *Curr Opin Hematol* 2001, **8**:85-91.
3. Camus D, Hadley TJ: **A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites.** *Science* 1985, **230**:553-556.
4. Orlandi PA, Klotz FW, Haynes JD: **A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of Plasmo-**

- dium falciparum* recognizes the terminal Neu5Ac(alpha 2-3)Gal-sequences of glycophorin A. *J Cell Biol* 1992, **116**:901-909.
5. Sim BK, Chitnis CE, Wasniowska K, Hadley TJ, Miller LH: **Receptor and ligand domains for invasion of erythrocytes by *Plasmodium falciparum***. *Science* 1994, **264**:1941-1944.
 6. Peterson DS, Miller LH, Wellem TE: **Isolation of multiple sequences from the *Plasmodium falciparum* genome that encode conserved domains homologous to those in erythrocyte-binding proteins**. *Proc Natl Acad Sci U S A* 1995, **92**:7100-7104.
 7. Sim BK, Orlandi PA, Haynes JD, Klotz FW, Carter JM, Camus D, Zegans ME, Chulay JD: **Primary structure of the 175 K *Plasmodium falciparum* erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion**. *J Cell Biol* 1990, **111**:1877-1884.
 8. Adams JH, Sim BK, Dolan SA, Fang X, Kaslow DC, Miller LH: **A family of erythrocyte binding proteins of malaria parasites**. *Proc Natl Acad Sci U S A* 1992, **89**:7085-7089.
 9. Orlandi PA, Sim BK, Chulay JD, Haynes JD: **Characterization of the 175-kilodalton erythrocyte binding antigen of *Plasmodium falciparum***. *Mol Biochem Parasitol* 1990, **40**:285-294.
 10. Ware LA, Kain KC, Lee Sim BK, Haynes JD, Baird JK, Lanar DE: **Two alleles of the 175-kilodalton *Plasmodium falciparum* erythrocyte binding antigen**. *Mol Biochem Parasitol* 1993, **60**:105-109.
 11. Okenu DM, Riley EM, Bickle QD, Agomo PU, Barbosa A, Daugherty JR, Lanar DE, Conway DJ: **Analysis of human antibodies to erythrocyte binding antigen 175 of *Plasmodium falciparum***. *Infect Immun* 2000, **68**:5559-5566.
 12. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, Sakihama N, Bojang KA, Oduola AM, Kremsner PG, Arnot DE, Greenwood BM, McBride JS: **A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses**. *Nat Med* 2000, **6**:689-962.
 13. Binks RH, Baum J, Oduola AM, Arnot DE, Babiker HA, Kremsner PG, Roper C, Greenwood BM, Conway DJ: **Population genetic analysis of the *Plasmodium falciparum* erythrocyte binding antigen-175 (eba-175) gene**. *Mol Biochem Parasitol* 2001, **114**:63-70.
 14. World Health Organization (WHO): **Severe falciparum malaria**. *Trans R Soc Trop Med Hyg* 2000, **94**(suppl 1):.
 15. Mockenhaupt FP, Ehrhardt S, Burkhardt J, Bosomtwe SY, Laryea S, Anemana SD, Otchwemah RN, Cramer J, Dietz E, Gellert S, Bienzle U: **Manifestation and outcome of severe malaria in children in northern Ghana**. *Am J Trop Med Hyg* in press.
 16. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellem TE, Plowe CV, Coulibaly D: **A molecular marker for chloroquine-resistant falciparum malaria**. *N Engl J Med* 2001, **344**:257-263.
 17. Touré FS, Mavoungou E, Ndong JM, Tshipamba P, Deloron P: **Erythrocyte binding antigen (EBA-175) of *Plasmodium falciparum*: improved genotype determination by nested polymerase chain reaction**. *Trop Med Int Health* 2001, **6**:767-769.
 18. Dittrich S, Schwobel B, Jordan S, Vanisaveth V, Rattanaxay P, Christophel EM, Phompida S, Jelinek T: **Distribution of the two forms of *Plasmodium falciparum* erythrocyte binding antigen-175 (eba-175) gene in Lao PDR**. *Malar J* 2003, **2**:23.
 19. Färnert A, Rooth I, Svensson A, Snounou G, Björkman A: **Complexity of *Plasmodium falciparum* infections is consistent over time and protects against clinical disease in Tanzanian children**. *J Infect Dis* 1999, **179**:989-995.
 20. Owusu-Agyei S, Smith T, Beck H-P, Amenga-Etego L, Felger I: **Molecular epidemiology of *Plasmodium falciparum* infections among asymptomatic inhabitants of a holoendemic malarious area in northern Ghana**. *Trop Med Int Health* 2002, **7**:421-8.
 21. Smith T, Felger I, Tanner M, Beck HP: **Premunition in *Plasmodium falciparum* infection: insights from the epidemiology of multiple infections**. *Trans R Soc Trop Med Hyg* 1999, **93**(Suppl 1):59-64.
 22. Binks RH, Conway DJ: **The major allelic dimorphisms in four *Plasmodium falciparum* merozoite proteins are not associated with alternative pathways of erythrocyte invasion**. *Mol Biochem Parasitol* 1999, **103**:123-127.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

